Andere Sprachen ImmunityBio, Inc.

Aktien

A2QQ2E

US45256X1037

IBRX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 19.04.2024			% 5 Tage	% 1. Jan.
5.27 ^USD	+7.33%		+3.13%	+4.98%

25.03.	IMMUNITYBIO, INC. : Piper Sandler bekräftigt seine neutrale Bewertung	ZM
19.03.	ImmunityBio, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

ImmunityBio Files Mixed Shelf	17.04.
North American Morning Briefing : Markets Steady -2-	26.03.
ImmunityBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19.03.
North American Morning Briefing : Stock Futures -2-	19.03.
NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy	06.03.
N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study	05.03.
ImmunityBio Announces Data from A Phase 1 Pilot Study	05.03.
ImmunityBio Says Cancer Vaccine Trial Moving to Controlled Phase	21.02.
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial	21.02.
ImmunityBio, Inc. Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial	21.02.
ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG	05.02.
Immunitybio, Inc. Announces Findings from Patient-Reported Outcomes of Participants in the Phase 2/3 Quilt 3.032 Study of N-803 Plus BCG	05.02.
US Equity Markets Close Lower Tuesday Ahead of Fed Meeting Minutes	02.01.
Sector Update: Health Care Stocks Gain Late Afternoon	02.01.
Sector Update: Health Care Stocks Rise Tuesday Afternoon	02.01.
ImmunityBio Secures $320 Million Investment From Oberland Capital	02.01.
Sector Update: Health Care	02.01.
Top Stories at Midday: US Construction Spending Up 0.4% in November; Avangrid-PNM Resources Deal Terminated; Terreno Realty Sells California Property for $15.9 Million; ImmunityBio Secures $320 Million Investment	02.01.
ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million	02.01.
ImmunityBio, Inc. announced that it has received $9.999194 million in funding	29.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen ImmunityBio, Inc.

Aktien

A2QQ2E

US45256X1037

IBRX

Andere Sprachen

Filter